A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : EP / E-type prostanoid

[Related PubMed/MEDLINE]
Total Number of Papers: 16
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   EP  (>> Co-occurring Abbreviation)
Long Form:   E-type prostanoid
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Distribution and Function of Prostaglandin E2 Receptors in Mouse Uterus: Translational Value for Human Reproduction. PG
2019 Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer. COX, PG
2018 Cellular density-dependent increases in HIF-1alpha compete with c-Myc to down-regulate human EP4 receptor promoter activity through Sp-1-binding region. ---
2017 PGE1 and E3 show lower efficacies than E2 to beta-catenin-mediated activity as biased ligands of EP4 prostanoid receptors. TCF
2017 Up-regulation of EP2 and EP3 receptors in human tolerogenic dendritic cells boosts the immunosuppressive activity of PGE2. DCs, mDCs, tolDCs
2016 The Coxib case: Are EP receptors really guilty? AA, ADMA, COX, l-NMMA, MI, NO, NOS, NSAIDs, PG, PGH2
2016 The Roles of EP4 Prostanoid Receptors in Cancer Malignancy Signaling. PGE2
2015 Hypodermin A, a potential agent for prevention of allogeneic acute rejection. HA, IFN, IL, PGE2
2015 Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets? COXIBs, NSAIDs
10  2014 Altered inhibitory function of the E-type prostanoid receptor 4 in eosinophils and monocytes from aspirin-intolerant patients. AERD, LPS, PG
11  2013 E-type prostanoid receptor 4 (EP4) in disease and therapy. EP4, PG
12  2013 Endothelial E-type prostanoid 4 receptors promote barrier function and inhibit neutrophil trafficking. PG
13  2013 Induction of cyclooxygenase-2 expression by prostaglandin E2 stimulation of the prostanoid EP4 receptor via coupling to Galphai and transactivation of the epidermal growth factor receptor in HCA-7 human colon cancer cells. COX-2, PGE2
14  2012 Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation. DP, IP, PG
15  2010 Assessment of constitutive activity in E-type prostanoid receptors. GPCRs
16  2000 Selective activation of E-type prostanoid(3)-receptors reduces myocardial infarct size. A novel insight into the cardioprotective effects of prostaglandins. PGs